Talk:Obinutuzumab
 | This article is rated Stub-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
| |||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Obinutuzumab.
|
New data
[edit]This article is very out of date.
1. It makes no mention of a positive phase III study --published in 2017!-- and subsequent worldwide approvals in 1L follicular lymphoma.
2. It might also be updated to reflect another recent positive phase III study in 1L CLL
ASCO conference abstract
[edit]Preliminary : ASCO: Antibody Boosts Chemo in CLL. June 2013. aka GA101 - Rod57 (talk) 07:12, 9 July 2013 (UTC)
Need a better summary of the 70 registered clinical trials
[edit]All trials using obinutuzumab shows 70 trials. Some completed for which there should be some announcements or published results. - Rod57 (talk) 01:56, 4 March 2016 (UTC)
- Only four are completed. I will look for recent reviews. You can do that yourself using the box at the top of this page. Jytdog (talk) 13:48, 4 March 2016 (UTC)
Clinical trials summary deleted from article
[edit]I removed the content below from the article and put it here. This is not appropriately sourced and the content cannot stand in WP like this. Parking it here for now.
- Clinical trials
- chronic lymphocytic leukemia
In 2014, the National Cancer Institute published the results of an international randomized phase III study in which they investigated the use of obinutuzumab in previously untreated patients with chronic lymphocytic leukemia (CLL) and other health conditions. When these patients were given obinutuzumab in combination with chlorambucil, a chemotherapeutic agent, they were found to live longer without their CLL progressing than patients who received only chlorambucil. The patients that received this combination therapy were more likely to go into complete remission as well as have better overall survival than those who received chlorambucil alone. In this study, they also compared patients treated with obinutuzumab and chlorambucil to patients that were treated with rituximab and chlorambucil.[1] When comparing CLL patients that received the obinutuzumab combination therapy versus the rituximab combination therapy, the researchers found that the obinutuzumab patients had higher rates of complete remission as well as longer progression-free survival.[1]
In a phase I study, the researchers are investigating the use of obinutuzumab in combination with venetoclax, a small molecule Bcl-2 inhibitor, to determine if this combination is more effective at treating CLL than obinutuzumab with chlorambucil.[2][3]
- Non-Hodgkins lymphomas
Another study is investigating the use of obinutuzumab with lenalidomide, an antineoplastic agent, in non-Hodgkins lymphomas (NHL).[4]
References
- ^ a b "Obinutuzumab Plus Chlorambucil for Chronic Lymphocytic Leukemia". National Cancer Institute. Retrieved 2015-11-30.
- ^ A Study of Venetoclax (GDC-0199; ABT-199) in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia
- ^ "Investor Update". www.roche.com. Retrieved 2015-11-30.
- ^ Lenalidomide and GA101 in Relapsed Indolent Non-Hodgkin's Lymphoma
- Jytdog (talk) 13:44, 4 March 2016 (UTC)
- Looks better sourced than much in WP and doesn't seem to overstate the sources. - Perhaps too wordy in 1st paragraph - what don't you like about it ? or how would you summarise it ? (some of it could probably be updated now) - Rod57 (talk) 19:33, 7 March 2018 (UTC)
Cost and cost effectiveness for the CLL approval
[edit]Maybe in a new section mention :
- [1] says "Cost of Gazyva is $41,300 for one 6-month course of treatment".
- UK NICE determination [2] says "The company stated that a course of treatment costs £26,496 (£9936 for cycle 1 and £3312 for cycles 2-6, excluding VAT)." and presents detailed cost effectiveness comparisions and discussions p13-24 - Rod57 (talk) 19:20, 7 March 2018 (UTC)